, Xiang Yu Gao2
, Wichit Srikureja1,2
, Jack Brandabur3, Shih-Ting Chiu4
, Nishant Puri1,2
1Pancreas and Liver Clinic, Providence Sacred Heart Medical Center, Spokane, WA, USA
2Elson S. Floyd School of Medicine, Washington State University, Spokane, WA, USA
3Prosser Memorial Health, Prosser, WA, USA
4Providence Saint Joseph Medical Center, Portland, OR, USA
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
Divyanshoo R. Kohli received consultancy, research support, and equipment loans from Fujifilm (current) and Olympus (completed) for unrelated projects; Nishant Puri served as a consultant for Boston Scientific (completed); all other authors have no potential conflicts of interest.
Funding
None.
Acknowledgments
The authors gratefully acknowledge the assistance of Ms. Julie Campbell in conducting this study.
Author Contributions
Conceptualization: DK; Investigation: DK,NP, JB,WS; Data curation: XG; Methodology: SC; Writing–original daft: DK; Writing–review & editing: XG, JB, NP, WS, SC.
| Characteristic | Overall (n=482) | Retained stent (n=158) | Stent migrated (n=267) | p-value |
|---|---|---|---|---|
| Demographics | ||||
| Age (yr) | 57.09±18.49 | 57.2±18.06 | 57.51±18.11 | 0.57 |
| Female | 264 (54.8) | 79 (50.0) | 154 (57.7) | 0.13 |
| White | 400 (83.0) | 138 (87.3) | 221 (82.8) | 0.27 |
| BMI (kg/m2) | 28.71±7.3 | 27.4±6.7 | 29.28±7.5 | 0.02 |
| Inpatient | 178 (36.9) | 53 (33.5) | 104 (39.0) | 0.29 |
| Indication for ERCP | ||||
| Biliary | 289 (60.0) | 51 (32.3) | 190 (71.2) | <0.01 |
| Choledocholithiasis | 148 (30.7) | 17 (10.8) | 97 (36.3) | |
| Bile leak | 33 (6.8) | 9 (5.7) | 24 (9.0) | |
| Biliary stricture | 22 (4.6) | 6 (3.8) | 11 (4.1) | |
| Elevated liver enzymes | 25 (5.2) | 3 (1.9) | 18 (6.7) | |
| Malignant obstruction | 42 (8.7) | 12 (7.6) | 27 (10.1) | |
| Miscellaneous | 19 (3.9) | 4 (2.5) | 13 (4.9) | |
| Pancreatic | 181 (37.6) | 98 (62.0) | 74 (27.7) | |
| Chronic pancreatitis | 97 (20.1) | 58 (36.7) | 34 (12.7) | |
| Pancreatic duct leak | 38 (7.9) | 15 (9.5) | 22 (8.2) | |
| Pancreas divisum | 13 (2.7) | 8 (5.1) | 5 (1.9) | |
| Pancreatic duct stricture | 18 (3.7) | 11 (7.0) | 7 (2.6) | |
| Miscellaneous | 15 (3.1) | 6 (3.8) | 6 (2.2) | |
| Both biliary and pancreatic | 12 (2.5) | 9 (5.7) | 3 (1.1) | |
| Indication for pancreatic duct stent | <0.01 | |||
| Pancreatitis prophylaxis | 313 (64.9) | 63 (39.9) | 209 (78.3) | |
| Chronic pancreatitis | 106 (22.0) | 64 (40.5) | 36 (13.5) | |
| Pancreatic duct leak | 24 (5.0) | 13 (8.2) | 10 (3.7) | |
| Pancreatic duct stricture | 18 (3.7) | 11 (7.0) | 7 (2.6) | |
| Pancreas divisum | 12 (2.5) | 7 (4.4) | 5 (1.9) |
| Overall (n=482) | Patients with long-term follow-up (n=425) | |||
|---|---|---|---|---|
| Retained stent (n=158) | Stent migrated (n=267) | p-value | ||
| Characteristics of pancreatic duct stent | ||||
| Diameter (Fr) | <0.01 | |||
| 4 | 191 | 19 | 144 | |
| 5 | 211 | 84 | 104 | |
| 7 | 73 | 51 | 16 | |
| 10 | 2 | 1 | 1 | |
| 7+5 | 5 | 3 | 2 | |
| Length (cm) | <0.01 | |||
| 2 | 2 | 1 | ||
| 3 | 289 | 61 | 214 | |
| 4 | 16 | 5 | 8 | |
| 5 | 62 | 43 | 19 | |
| 6 | 4 | 3 | ||
| 7 | 45 | 34 | 10 | |
| 8 | 10 | 4 | 6 | |
| 9 | 20 | 11 | 6 | |
| Fluoroscopy (sec) | 64 (33–152) | 98 (39–185) | 50 (26–128) | <0.01 |
| Internal flange present | 208 | 129 | 65 | <0.01 |
| Outcomes | ||||
| Post-ERCP pancreatitis | 20 | 8 | 11 | 0.59 |
| Bleeding | 3 | 2 | 1 | 0.6 |
| Parameter | OR (95% CI) | p-value |
|---|---|---|
| Stent characteristics | ||
| Presence of an internal flange | 6.39 (3.29–12.67) | <0.001 |
| Length >3 cm | 2.5 (1.23–5.07) | 0.01 |
| Diameter ≥5 Fr | 1.36 (0.62–3.01) | 0.44 |
| Patient characteristics | ||
| Pancreatic indication for ERCP | 2.23 (1.22–4.07) | 0.008 |
| Inpatient status | 0.59 (0.33–1.05) | 0.07 |
| Male sex | 0.63 (0.35–1.08) | 0.1 |
| Parameter | OR (95% CI) | p-value |
|---|---|---|
| Stent features | ||
| Diameter >5 Fr | 0.28 (0.12–0.62) | 0.002 |
| Length >3 cm | 0.28 (0.15–0.52) | 0.0001 |
| Internal flange present | 0.86 (0.39–1.92) | NS |
| Outcomes | ||
| Post-ERCP pancreatitis | 0.63 (0.17–2.33) | NS |
| Stent retention | 0.46 (0.26–0.83) | 0.009 |
Values are presented as mean±standard deviation or number (%). BMI, body mass index; ERCP, endoscopic retrograde cholangiopancreatography.
Values are presented as number or median (interquartile range). ERCP, endoscopic retrograde cholangiopancreatography.
ERCP, endoscopic retrograde cholangiopancreatography; OR, odds ratio; CI, confidence interval.
OR, odds ratio; CI, confidence interval; NS, not significant; ERCP, endoscopic retrograde cholangiopancreatography.
